VCP
MRNA icon

Verus Capital Partners’s Moderna MRNA Stock Holding History

Verus Capital Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$86K Buy
+2,880
New +$66.3K 0.03% 346

Other funds holding MRNA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Verus Capital Partners's MRNA Position: Q1 2020 in Review

Verus Capital Partners opened a new position in Moderna (MRNA) in Q1 2020: 2,880 shares worth $86K. The stake represents 0.03% of the portfolio and ranks #346 among its holdings.

300 funds tracked by Wall St. Rank hold MRNA as of Q1 2020.

  • Verus Capital Partners held 2,880 shares of Moderna worth $86K as of Q1 2020.
  • Moderna was a new Verus Capital Partners position in Q1 2020.
  • Moderna made up 0.03% of Verus Capital Partners's portfolio in Q1 2020, its #346 holding.
  • 300 funds tracked by Wall St. Rank held Moderna as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.